Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 May 1;99(9):2260–2268. doi: 10.1172/JCI119401

Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids.

H Takeya 1, T Mori 1, E C Gabazza 1, K Kuroda 1, H Deguchi 1, E Matsuura 1, K Ichikawa 1, T Koike 1, K Suzuki 1
PMCID: PMC508058  PMID: 9151800

Abstract

beta2-Glycoprotein I (beta2GPI), a plasma glycoprotein with phospholipid-binding property, is known to be the actual target antigen for autoimmune type anticardiolipin antibodies (aCLs). Certain groups of aCLs (anti-beta2GPI antibodies) exert lupus anticoagulant (LA) activity and perturb the function of vascular endothelial cells. This investigation aimed at highlighting some insights into the molecular basis by which aCLs exert their biological effects by using anti-beta2GPI mAbs with well-characterized epitopes from mice and from patients with antiphospholipid syndrome. Anti-beta2GPI mAbs directed against the third domain (Cof-20 and Cof-22) and fourth domain (Cof-21, EY1C8, and EY2C9) of beta2GPI inhibited the thrombin generation induced by Russell's viper venom in diluted plasma and that induced by the prothrombinase complex reconstituted with purified clotting factors. This anticoagulant activity was abrogated in the presence of an excess amount of phospholipids, thus resembling the LA activity. In stark contrast, anti-beta2GPI mAbs directed against the fifth domain and the carboxy-terminal region of the fourth domain showed no LA-like activity. These findings suggest that the LA activity of anti-beta2GPI antibodies depends on their epitope specificity. Experiments carried out to clarify the mechanism of the LA activity showed that anti-beta2GPI mAbs with LA-like activity, but not those without this effect, enhance the beta2GPI binding to phospholipids. In addition, the F(ab')2 fragment, but not the Fab' fragment, of the anti-beta2GPI mAbs was found to enhance the LA activity and the beta2GPI binding to phospholipids, suggesting that anti-beta2GPI antibodies induce formation of multiple complexes of beta2GPI on the surface of phospholipids because of their bivalent property. This clustering of beta2GPI molecules induced by anti-beta2GPI antibodies, probably because of their multivalent property and epitope specificity, might hinder the lateral mobility and activation of clotting factors on the surface of phospholipids and thus exert LA activity. Clustering of beta2GPI molecules may also explain the molecular mechanism by which anti-beta2GPI antibodies alter the function of leukocytes and endothelial cells. The well-documented heterogeneous LA activity of aCLs (anti-beta2GPI antibodies) may also be explained by their epitope specificity.

Full Text

The Full Text of this article is available as a PDF (259.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost. 1996 Apr;75(4):536–541. [PubMed] [Google Scholar]
  2. Bakimer R., Fishman P., Blank M., Sredni B., Djaldetti M., Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest. 1992 May;89(5):1558–1563. doi: 10.1172/JCI115749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bevers E. M., Galli M., Barbui T., Comfurius P., Zwaal R. F. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost. 1991 Dec 2;66(6):629–632. [PubMed] [Google Scholar]
  4. Bick R. L., Baker W. F. Antiphospholipid and thrombosis syndromes. Semin Thromb Hemost. 1994;20(1):3–15. doi: 10.1055/s-2007-1001885. [DOI] [PubMed] [Google Scholar]
  5. Blank M., Cohen J., Toder V., Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3069–3073. doi: 10.1073/pnas.88.8.3069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Blank M., Faden D., Tincani A., Kopolovic J., Goldberg I., Gilburd B., Allegri F., Balestrieri G., Valesini G., Shoenfeld Y. Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun. 1994 Aug;7(4):441–455. doi: 10.1006/jaut.1994.1032. [DOI] [PubMed] [Google Scholar]
  7. Brandt J. T. Antibodies to beta 2-glycoprotein I inhibit phospholipid dependent coagulation reactions. Thromb Haemost. 1993 Oct 18;70(4):598–602. [PubMed] [Google Scholar]
  8. Exner T., Sahman N., Trudinger B. Separation of anticardiolipin antibodies from lupus anticoagulant on a phospholipid-coated polystyrene column. Biochem Biophys Res Commun. 1988 Sep 15;155(2):1001–1007. doi: 10.1016/s0006-291x(88)80596-5. [DOI] [PubMed] [Google Scholar]
  9. Exner T., Triplett D. A., Taberner D., Machin S. J. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost. 1991 Mar 4;65(3):320–322. [PubMed] [Google Scholar]
  10. Galli M., Comfurius P., Barbui T., Zwaal R. F., Bevers E. M. Anticoagulant activity of beta 2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost. 1992 Sep 7;68(3):297–300. [PubMed] [Google Scholar]
  11. Galli M., Comfurius P., Maassen C., Hemker H. C., de Baets M. H., van Breda-Vriesman P. J., Barbui T., Zwaal R. F., Bevers E. M. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990 Jun 30;335(8705):1544–1547. doi: 10.1016/0140-6736(90)91374-j. [DOI] [PubMed] [Google Scholar]
  12. Galli M., Finazzi G., Bevers E. M., Barbui T. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies. Blood. 1995 Jul 15;86(2):617–623. [PubMed] [Google Scholar]
  13. Gharavi A. E., Sammaritano L. R., Wen J., Elkon K. B. Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H). J Clin Invest. 1992 Sep;90(3):1105–1109. doi: 10.1172/JCI115927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ginsberg J. S., Demers C., Brill-Edwards P., Johnston M., Bona R., Burrows R. F., Weitz J., Denburg J. A. Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state. Blood. 1993 Jun 1;81(11):2958–2963. [PubMed] [Google Scholar]
  15. Hagihara Y., Goto Y., Kato H., Yoshimura T. Role of the N- and C-terminal domains of bovine beta 2-glycoprotein I in its interaction with cardiolipin. J Biochem. 1995 Jul;118(1):129–136. doi: 10.1093/oxfordjournals.jbchem.a124867. [DOI] [PubMed] [Google Scholar]
  16. Hashimoto Y., Kawamura M., Ichikawa K., Suzuki T., Sumida T., Yoshida S., Matsuura E., Ikehara S., Koike T. Anticardiolipin antibodies in NZW x BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol. 1992 Aug 1;149(3):1063–1068. [PubMed] [Google Scholar]
  17. Hunt J. E., Simpson R. J., Krilis S. A. Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2141–2145. doi: 10.1073/pnas.90.6.2141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hunt J., Krilis S. The fifth domain of beta 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol. 1994 Jan 15;152(2):653–659. [PubMed] [Google Scholar]
  19. Ichikawa K., Khamashta M. A., Koike T., Matsuura E., Hughes G. R. beta 2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum. 1994 Oct;37(10):1453–1461. doi: 10.1002/art.1780371008. [DOI] [PubMed] [Google Scholar]
  20. Igarashi M., Matsuura E., Igarashi Y., Nagae H., Ichikawa K., Triplett D. A., Koike T. Human beta2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system. Blood. 1996 Apr 15;87(8):3262–3270. [PubMed] [Google Scholar]
  21. Igarashi M., Matsuura E., Igarashi Y., Nagae H., Matsuura Y., Ichikawa K., Yasuda T., Voelker D. R., Koike T. Expression of anticardiolipin cofactor, human beta 2-glycoprotein I, by a recombinant baculovirus/insect cell system. Clin Exp Immunol. 1993 Jul;93(1):19–25. doi: 10.1111/j.1365-2249.1993.tb06491.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Iino M., Takeya H., Nishioka J., Nakagaki T., Tamura K., Suzuki K. The role of human factor X activation peptide in activation of factor X by factor IXa. J Biochem. 1994 Aug;116(2):335–340. doi: 10.1093/oxfordjournals.jbchem.a124528. [DOI] [PubMed] [Google Scholar]
  23. Kane W. H., Majerus P. W. Purification and characterization of human coagulation factor V. J Biol Chem. 1981 Jan 25;256(2):1002–1007. [PubMed] [Google Scholar]
  24. Kato H., Enjyoji K. Amino acid sequence and location of the disulfide bonds in bovine beta 2 glycoprotein I: the presence of five Sushi domains. Biochemistry. 1991 Dec 17;30(50):11687–11694. doi: 10.1021/bi00114a012. [DOI] [PubMed] [Google Scholar]
  25. Koike T. Anticardiolipin antibodies and beta 2-glycoprotein I. Clin Immunol Immunopathol. 1994 Aug;72(2):187–192. doi: 10.1006/clin.1994.1128. [DOI] [PubMed] [Google Scholar]
  26. Koike T., Matsuura E. What is the "true" antigen for anticardiolipin antibodies? Lancet. 1991 Mar 16;337(8742):671–672. doi: 10.1016/0140-6736(91)92482-h. [DOI] [PubMed] [Google Scholar]
  27. Kornberg A., Blank M., Kaufman S., Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol. 1994 Aug 1;153(3):1328–1332. [PubMed] [Google Scholar]
  28. Kostetskii E. Ia, Gerasimenko N. I., Kushnerova N. F. [The phospholipid composition of organs and tissues of rabbit]. Biokhimiia. 1977 Apr;42(4):672–676. [PubMed] [Google Scholar]
  29. Lozier J., Takahashi N., Putnam F. W. Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc Natl Acad Sci U S A. 1984 Jun;81(12):3640–3644. doi: 10.1073/pnas.81.12.3640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Malia R. G., Kitchen S., Greaves M., Preston F. E. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol. 1990 Sep;76(1):101–107. doi: 10.1111/j.1365-2141.1990.tb07843.x. [DOI] [PubMed] [Google Scholar]
  31. Malm J., Persson U., Dahlbäck B. Inhibition of human vitamin-K-dependent protein-S-cofactor activity by a monoclonal antibody specific for a Ca2+-dependent epitope. Eur J Biochem. 1987 May 15;165(1):39–45. doi: 10.1111/j.1432-1033.1987.tb11191.x. [DOI] [PubMed] [Google Scholar]
  32. Mann K. G., Krishnaswamy S., Lawson J. H. Surface-dependent hemostasis. Semin Hematol. 1992 Jul;29(3):213–226. [PubMed] [Google Scholar]
  33. Martinuzzo M. E., Forastiero R. R., Carreras L. O. Anti beta 2 glycoprotein I antibodies: detection and association with thrombosis. Br J Haematol. 1995 Feb;89(2):397–402. doi: 10.1111/j.1365-2141.1995.tb03317.x. [DOI] [PubMed] [Google Scholar]
  34. Matsuda J., Gohchi K., Kawasugi K., Gotoh M., Saitoh N., Tsukamoto M. Inhibitory activity of anti-beta 2-glycoprotein I antibody on factor Va degradation by activated-protein C and its cofactor protein S. Am J Hematol. 1995 May;49(1):89–91. doi: 10.1002/ajh.2830490116. [DOI] [PubMed] [Google Scholar]
  35. Matsuda J., Gotoh M., Gohchi K., Kawasugi K., Tsukamoto M., Saitoh N. Resistance to activated protein C activity of an anti-beta 2-glycoprotein I antibody in the presence of beta 2-glycoprotein I. Br J Haematol. 1995 May;90(1):204–206. doi: 10.1111/j.1365-2141.1995.tb03401.x. [DOI] [PubMed] [Google Scholar]
  36. Matsuura E., Igarashi M., Igarashi Y., Katahira T., Nagae H., Ichikawa K., Triplett D. A., Koike T. Molecular studies on phospholipid-binding sites and cryptic epitopes appearing on beta 2-glycoprotein I structure recognized by anticardiolipin antibodies. Lupus. 1995 Feb;4 (Suppl 1):S13–S17. doi: 10.1177/096120339400400104. [DOI] [PubMed] [Google Scholar]
  37. Matsuura E., Igarashi M., Igarashi Y., Nagae H., Ichikawa K., Yasuda T., Koike T. Molecular definition of human beta 2-glycoprotein I (beta 2-GPI) by cDNA cloning and inter-species differences of beta 2-GPI in alternation of anticardiolipin binding. Int Immunol. 1991 Dec;3(12):1217–1221. doi: 10.1093/intimm/3.12.1217. [DOI] [PubMed] [Google Scholar]
  38. Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 1990 Jul 21;336(8708):177–178. doi: 10.1016/0140-6736(90)91697-9. [DOI] [PubMed] [Google Scholar]
  39. Matsuura E., Igarashi Y., Yasuda T., Triplett D. A., Koike T. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med. 1994 Feb 1;179(2):457–462. doi: 10.1084/jem.179.2.457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. McNeil H. P., Chesterman C. N., Krilis S. A. Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics. Br J Haematol. 1989 Dec;73(4):506–513. doi: 10.1111/j.1365-2141.1989.tb00289.x. [DOI] [PubMed] [Google Scholar]
  41. McNeil H. P., Chesterman C. N., Krilis S. A. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol. 1991;49:193–280. doi: 10.1016/s0065-2776(08)60777-4. [DOI] [PubMed] [Google Scholar]
  42. McNeil H. P., Simpson R. J., Chesterman C. N., Krilis S. A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990 Jun;87(11):4120–4124. doi: 10.1073/pnas.87.11.4120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Miletich J. P., Broze G. J., Jr, Majerus P. W. The synthesis of sulfated dextran beads for isolation of human plasma coagulation factors II, IX, and X. Anal Biochem. 1980 Jul 1;105(2):304–310. doi: 10.1016/0003-2697(80)90462-5. [DOI] [PubMed] [Google Scholar]
  44. Nimpf J., Bevers E. M., Bomans P. H., Till U., Wurm H., Kostner G. M., Zwaal R. F. Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I. Biochim Biophys Acta. 1986 Oct 29;884(1):142–149. doi: 10.1016/0304-4165(86)90237-0. [DOI] [PubMed] [Google Scholar]
  45. Nonaka M., Matsuda Y., Shiroishi T., Moriwaki K., Nonaka M., Natsuume-Sakai S. Molecular cloning of mouse beta 2-glycoprotein I and mapping of the gene to chromosome 11. Genomics. 1992 Aug;13(4):1082–1087. doi: 10.1016/0888-7543(92)90022-k. [DOI] [PubMed] [Google Scholar]
  46. Oosting J. D., Derksen R. H., Entjes H. T., Bouma B. N., de Groot P. G. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb Haemost. 1992 May 4;67(5):499–502. [PubMed] [Google Scholar]
  47. Parham P. On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice. J Immunol. 1983 Dec;131(6):2895–2902. [PubMed] [Google Scholar]
  48. Permpikul P., Rao L. V., Rapaport S. I. Functional and binding studies of the roles of prothrombin and beta 2-glycoprotein I in the expression of lupus anticoagulant activity. Blood. 1994 May 15;83(10):2878–2892. [PubMed] [Google Scholar]
  49. Reeves W. H., Blankson J., Chou C. H. Molecular analysis of autoantibody production. Concepts Immunopathol. 1992;8:38–70. [PubMed] [Google Scholar]
  50. Roubey R. A. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood. 1994 Nov 1;84(9):2854–2867. [PubMed] [Google Scholar]
  51. Roubey R. A., Eisenberg R. A., Harper M. F., Winfield J. B. "Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol. 1995 Jan 15;154(2):954–960. [PubMed] [Google Scholar]
  52. Schousboe I. Inositolphospholipid-accelerated activation of prekallikrein by activated factor XII and its inhibition by beta 2-glycoprotein I. Eur J Biochem. 1988 Oct 1;176(3):629–636. doi: 10.1111/j.1432-1033.1988.tb14323.x. [DOI] [PubMed] [Google Scholar]
  53. Schousboe I. beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood. 1985 Nov;66(5):1086–1091. [PubMed] [Google Scholar]
  54. Shi W., Chong B. H., Chesterman C. N. Beta 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood. 1993 Mar 1;81(5):1255–1262. [PubMed] [Google Scholar]
  55. Simantov R., LaSala J. M., Lo S. K., Gharavi A. E., Sammaritano L. R., Salmon J. E., Silverstein R. L. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest. 1995 Nov;96(5):2211–2219. doi: 10.1172/JCI118276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Smirnov M. D., Esmon C. T. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem. 1994 Jan 14;269(2):816–819. [PubMed] [Google Scholar]
  57. Steinkasserer A., Barlow P. N., Willis A. C., Kertesz Z., Campbell I. D., Sim R. B., Norman D. G. Activity, disulphide mapping and structural modelling of the fifth domain of human beta 2-glycoprotein I. FEBS Lett. 1992 Nov 23;313(2):193–197. doi: 10.1016/0014-5793(92)81442-o. [DOI] [PubMed] [Google Scholar]
  58. Suzuki K., Dahlbäck B., Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem. 1982 Jun 10;257(11):6556–6564. [PubMed] [Google Scholar]
  59. Tamoto K., Koyama J. Non-precipitating guinea-pig antibodies as products of limited recognition of antigenic sites on the ovalbumin molecule. Immunology. 1976 Jul;31(1):67–77. [PMC free article] [PubMed] [Google Scholar]
  60. Thiagarajan P., Shapiro S. S., De Marco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest. 1980 Sep;66(3):397–405. doi: 10.1172/JCI109869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Triplett D. A. Antiphospholipid antibodies and thrombosis. A consequence, coincidence, or cause? Arch Pathol Lab Med. 1993 Jan;117(1):78–88. [PubMed] [Google Scholar]
  62. Triplett D. A. Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb Res. 1995 Apr 1;78(1):1–31. doi: 10.1016/0049-3848(95)00001-1. [DOI] [PubMed] [Google Scholar]
  63. Viard J. P., Amoura Z., Bach J. F. Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med. 1992 Aug;93(2):181–186. doi: 10.1016/0002-9343(92)90049-h. [DOI] [PubMed] [Google Scholar]
  64. Willems G. M., Janssen M. P., Pelsers M. M., Comfurius P., Galli M., Zwaal R. F., Bevers E. M. Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes. Biochemistry. 1996 Oct 29;35(43):13833–13842. doi: 10.1021/bi960657q. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES